Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508636 · ClinicalTrials.gov registry record · Phase 2
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02508636 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 11 participants.
The verdict
NCT02508636, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase II trial studies the safety of giving enzalutamide with leuprolide acetate before and after radiation therapy and to see how well it works in treating patients with prostate cancer that is at high risk of returning. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Most types of prostate cancer also need testosterone to grow and spread. After radiation therapy, patients often receive treatments to reduce testosterone to prevent the cancer from returning. Leuprolide acetate works by reducing the amount of testosterone that the body makes. Enzalutamide is a stronger treatment that may block testosterone from reaching cancer cells. Adding enzalutamide to treatment with leuprolide acetate after radiation therapy may help prevent high-risk prostate cancer from returning and improve patient survival.
Interventions
- DRUG Enzalutamide
- RADIATION Intensity-Modulated Radiation Therapy
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02508636
The ClinicalTrials.gov registry entry for NCT02508636 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT02508636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02508636 about?
NCT02508636 is a clinical study titled "Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer". This phase II trial studies the safety of giving enzalutamide with leuprolide acetate before and after radiation therapy and to see how well it works in treating patients with prostate cancer that is at high risk of returning. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink ...
What is the current status of trial NCT02508636?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-12-22. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT02508636?
The interventions under investigation include: Enzalutamide (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT02508636?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.